Tag Archive for: immuno-oncology

The company declined to exercise the license option for Harpoon Therapeutics’ TriTAC HPN217 program for multiple myeloma, which targets B cell maturation antigen, or BCMA.

The FDA has approved Jemperli as an add-on to chemotherapy for patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient or microsatellite instability-high.

Blockbuster deals are on the rise as drug manufacturers navigate through patent cliffs, pricing pressures, and evolving regulations while M&A activity remains an integral part of the strategic landscape.

Monday, Astellas named a new president and CEO and announced additional changes to its leadership structure in an effort to accelerate growth and chart its long-term business trajectory.

Junshi Biosciences’ Neotorch is the world’s first registered Phase III immuno-oncology trial for lung cancer to post positive EFS (event-free survival) data.

Seattle-based Alpine Immune Sciences voluntarily terminated enrollment in two clinical trials of its immuno-oncology asset, davoceticept, after a second patient death. The company now plans to focus its attention on ALPN-303 for autoantibody-related inflammatory diseases.

A separation of Sandoz via a 100 percent spin-off will create the leading European generics company and a global leader in biosimilars, and a more focused Novartis.

Elevation Oncology, Janssen, Merck and Teclison discuss the latest innovations in immuno-oncology.

Roche acquired privately held Good Therapeutics and its immuno-oncology platforms for $250 million, plus future milestone payments, on Wednesday. 

Clinical-stage biopharma company Mersana Therapeutics unveiled a global collaboration with GlaxoSmithKline Monday that gives the industry behemoth the exclusive option to co-develop and commercialize Mersana’s antibody-drug conjugate (ADC) XMT-2056.